Xinhua Pharma Obtains Three Drug Certificates from Chinese Regulator

MT Newswires Live
Sep 18

Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) and a unit recently obtained drug registration certificates for three drugs from China's National Medical Products Administration.

The company got a certificate for Levocarnitine Oral Solution, used for the treatment of primary systemic carnitine deficiency.

Its Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Concentrate Oral Solution, which is used for bowel cleaning in adults before any operation requiring intestinal cleansing, also got a registration certificate.

Unit Shandong Zibo Xincat Pharmaceutical got the third certificate for its Donepezil Hydrochloride Orally Disintegrating Tablets for the treatment of mild, moderate or severe symptoms of Alzheimer's disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10